

OSNA[®] – Now on the RD-210 Faster results – more flexibility – greater efficiency



We launched OSNA[®], or One step Nucleic Acid Amplification, in 2008 as a new and innovative method for analysing lymph nodes. Over the last decade, many hospitals have adopted OSNA[®] in routine and clinicians and patients have experienced the benefits of a highly accurate lymph node examination, the prompt availability of results and the significant value of the information delivered to them.

To date, more than 100 publications are available reporting the clinical value of the OSNA® method. Diagnostic information, expressed as CK19 mRNA copy number, has been shown to provide more differentiated information than the conventional classification of micro-/macrometastases, and that provided by histology.

In breast cancer in particular, data show that the copy number of the sentinel lymph node is predictive for further axillary node involvement [1] and also has prognostic value [2]. Based on the evidence, the method has been included in several breast cancer guidelines on a national and European level.

For colon cancer, the application offers an in-depth examination of a large number of lymph nodes.

Overlooking small metastasis can be avoided so that it delivers more precise staging and a more reliable basis for treatment decisions.

Based on the experience gained in the last decade, and on significant feedback from clients and patients, the system has been adapted to take into account the needs of modern healthcare providers in cancer management. With the new RD-210, handling and workflow are adapted to deliver a smoother process making the best possible use of resources in institutions.

On the pages overleaf you will find an insight into the experience of some long-term users who have experienced the new system in practice.

DIAGNOSTICS



Faster than before with greater flexibility

In hospitals, clinicians expect rapid, accurate results from the (pathology) laboratory so that they can decide how to treat their patients. With a turnaround time (TAT) of just 16 minutes for a single sample, the RD-210 diagnostic platform delivers quick results so that clinicians are more flexible in the intraoperative setting. If they need more, results for up to 14 lymph nodes can be provided within one run within 30 minutes. Furthermore, the RD-210 will process lymph node tissue from different patients or cancer types in parallel. 'Being able to provide results from the sentinel lymph nodes to the surgeons in the theatre room at least seven minutes faster than before is a key benefit. We can now better manage our patients and reduce theatre times. The option to run samples from different cancer entities together is also useful in terms of expanding the use of OSNA[®] for colon cancer.'

Prof. R. Boldorini, Head of Pathology Unit, Department of Health Sciences, University of Eastern Piedmont and A.O.U. Maggiore della Carità, Novara

Key new benefits:

- Expansion to maximum capacity of 14 samples
- Improved assay design to shorten TAT
- Combination of different cancer entities in one run





QR code – Your safety net for reagent management

Traceability of lot usage, monitoring freeze thaw cycles and reagent consumption – this is now all supported by:

- a QR-coded amplification kit (LYNOAMP CK19 E)
- an integrated barcode reader
- related software features

'The reagent management by QR code helps to avoid potential operator handling errors. This in turn helps us to provide high diagnostic quality for the patients and helps laboratories in general to fulfil requirements related to ISO standards and QM processes.'

Dr. V. Peg, MD, PhD, Pathologist, Vall d'Hebron University Hospital, Barcelona

By revising the kit concept, we offer greater flexibility to adapt to unexpected demands as they occur in daily routine (e.g. larger number of samples than initially planned) and reagent usage is more efficient than before.

"The reagent management has been nicely simplified." "We were able to The new vials with fixed lids are also easier to use." avoid waste. We Dr. F. Godey, Molecular Biologist, Centre Eugène Marquis, Rennes tion frequency,

'We were able to optimise the use of the kits and avoid waste. We observed a reduction in calibration frequency, saving time and being more efficient in particular in case of high sample numbers.'

Dr G. Nicosia, Chief of Pathology Laboratory, A.O.U. Maggiore della Carità, Novara





RD-210



'Thanks to the higher sample capacity, we can now avoid 2-3 extra runs when processing higher numbers of samples.'

M. Monteoliva, Lab technician, Vall d'Hebron University Hospital, Barcelona

'As we often have to manage parallel surgeries, we can now provide more results for more patients very quickly.'

Dr. F. Godey, Molecular Biologist, Centre Eugène Marquis, Rennes

RD-210



Compact design and easy operation

The new RD-210 is now more compact thanks to its integrated user interface operated by touch screen. More intuitive and user-friendly, the software delivers a clear structure for daily routine.

'The new software structure guides you smoothly through routine workflow steps. It is easy to use and helps us to save time. For example, when the analyser run is finished, results are accessible automatically on the screen.'

The new instrument requires less space due to its compact design. The soft design lines make it easy to clean the device – which we find essential in maintaining an optimal molecular working environment.'

N. Bravo, Lab technician, Vall d'Hebron University Hospital, Barcelona

'The software is easy to manage, including setting up calibration and analysis runs.'

Dr G. Nicosia, Chief of Pathology Laboratory, A.O.U. Maggiore della Carità, Novara

With the RD-210, OSNA[®] is entering a new phase.

'The RD-210 is far better than its predecessor in terms of usability, speed of operation and analysis.'

Dr. V. Peg, MD, PhD, Pathologist, Vall d'Hebron University Hospital, Barcelona







Key specifications

Model

Method **Diagnostic Parameter** Sample loading capacity Throughput

Dimensions / weight w x h x d [mm/kg]

Gene Amplification Detector RD-210

OSNA® (One Step Nucleic Acid Amplification) CK19 mRNA up to 14 samples 1 sample / batch: within 16 min 14 samples / batch: within 30 min 600 x 610 x 780 / approx. 90



References

- [1] Ohi Y et al. (2012): Whole sentinel lymph node analysis by a molecular assay predicts axillary node status in breastcancer. Br J Cancer. 107(8):1239 43.
- [2] Peg V et al. (2017): Role of total tumour load of sentinel lymph node on survival in early breast cancer patients. Breast. 2017 Feb 27; 33:8-13.

Authorised representative: Sysmex Europe GmbH Bornbarch 1, 22848 Norderstedt, Germany · Phone +49 40 52726-0 · Fax +49 40 52726-100 · lifescience@sysmex-europe.com · www.sysmex-europe.com

Manufacturer: Sysmex Corporation 1-5-1 Wakinohama-Kaigandori, Chuo-ku, Kobe 651-0073, Japan · Phone +81 78 265-0500 · Fax +81 78 265-052 · www.sysmex.co.jp You will find your local Sysmex representative's address under www.sysmex-europe.com/contacts